Table 1

CD19 and CD21 expression levels and cytotoxicity of hBU12 -vcMMAE against ALL, CLL, and NHL tumor cell lines grown in culture

Tumor type / cell lineCD21, copy no.CD19, copy no.IC50, nM hBU12-vcMMAEIC50, nM free MMAE
ALL     
    Nalm-6 53773 4.0 ± 0.05 0.65 ± 0.07 
    RS4;11 38227 0.050 ± 0.007 0.080 ± 0.007 
Transformed follicular lymphoma     
    DOHH2 40056 4.5 ± 0.7 0.200 ± 0.005 
    WSU-NHL 36242 0.35 ± 0.07 0.200 ± 0.005 
DLBCL     
    HT 952 36834 0.20 ± 0.04 0.103 ± 0.002 
    RL 32542 > 300 0.25 ± 0.07 
    WSU-DLCL2 19924 51 ± 0.71 0.30 ± 0.01 
    SUDHL-6 13784 0.04 ± 0.01 0.136 ± 0.003 
    SUDHL-4 38932 99 ± 15 0.71 ± 0.07 
Burkitt     
    CA46 2167 57240 1.4 ± 0.8 0.53 ± 0.09 
    Namalwa 374 28629 45 ± 29 0.31 ± 0.10 
    Ramos 2369 41016 0.60 ± 0.28 0.15 ± 0.01 
    Daudi 25531 54074 30 ± 2 0.193 ± 0.007 
    Raji 56660 78798 33.3 ± 7.1 0.43 ± 0.06 
Large B-cell lymphoma     
    ARH-77 29537 54324 126 ± 31 0.63 ± 0.16 
CLL     
    MEC-2 33246 67562 > 300 2 ± 0.6 
    JVM3 17850 26321 42 ± 5 0.20 ± 0.07 
T-cell leukemia     
    Jurkat: CD19 > 300 > 300 0.25 ± 0.04 
Tumor type / cell lineCD21, copy no.CD19, copy no.IC50, nM hBU12-vcMMAEIC50, nM free MMAE
ALL     
    Nalm-6 53773 4.0 ± 0.05 0.65 ± 0.07 
    RS4;11 38227 0.050 ± 0.007 0.080 ± 0.007 
Transformed follicular lymphoma     
    DOHH2 40056 4.5 ± 0.7 0.200 ± 0.005 
    WSU-NHL 36242 0.35 ± 0.07 0.200 ± 0.005 
DLBCL     
    HT 952 36834 0.20 ± 0.04 0.103 ± 0.002 
    RL 32542 > 300 0.25 ± 0.07 
    WSU-DLCL2 19924 51 ± 0.71 0.30 ± 0.01 
    SUDHL-6 13784 0.04 ± 0.01 0.136 ± 0.003 
    SUDHL-4 38932 99 ± 15 0.71 ± 0.07 
Burkitt     
    CA46 2167 57240 1.4 ± 0.8 0.53 ± 0.09 
    Namalwa 374 28629 45 ± 29 0.31 ± 0.10 
    Ramos 2369 41016 0.60 ± 0.28 0.15 ± 0.01 
    Daudi 25531 54074 30 ± 2 0.193 ± 0.007 
    Raji 56660 78798 33.3 ± 7.1 0.43 ± 0.06 
Large B-cell lymphoma     
    ARH-77 29537 54324 126 ± 31 0.63 ± 0.16 
CLL     
    MEC-2 33246 67562 > 300 2 ± 0.6 
    JVM3 17850 26321 42 ± 5 0.20 ± 0.07 
T-cell leukemia     
    Jurkat: CD19 > 300 > 300 0.25 ± 0.04 

IC50 values were determined by incubation of the tumor cell lines for 96 hours to the hBU12-vcMMAE conjugate or MMAE, as indicated. Cell lines, in which less than 50% cytotoxicity was achieved at concentrations greater than or equal to 300 nM, were considered nonresponsive. Both unconjugated hBU12 and a control, nonbinding vcMMAE conjugate exhibited negligible antitumor activities against these cell lines. All values obtained for hBU12-vcMMAE are significantly different from control-vcMMAE compounds tested in the same assay (Student t test, data not shown). Jurkat cells were used as a CD19 control cell line. The absence of activity of hBU12-vcMMAE on these control cells suggested that the antitumor activity is immunologically specific. Data shown represent the mean plus or minus SD of three replicates from 2 independent experiments.